What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets

Low target discovery rate has been linked to inadequate consideration of multiple factors that collectively contribute to druggability. These factors include sequence, structural, physicochemical, and systems profiles. Methods individually exploring each of these profiles for target identification have been developed, but they have not been collectively used. We evaluated the collective capability of these methods in identifying promising targets from 1019 research targets based on the multiple profiles of up to 348 successful targets. The collective method combining at least three profiles identified 50, 25, 10, and 4% of the 30, 84, 41, and 864 phase III, II, I, and nonclinical trial targets as promising, including eight to nine targets of positive phase III results. This method dropped 89% of the 19 discontinued clinical trial targets and 97% of the 65 targets failed in high-throughput screening or knockout studies. Collective consideration of multiple profiles demonstrated promising potential in identifying innovative targets.

[1]  Caitlin Smith,et al.  A question of form , 2003, Nature.

[2]  D. Simmons.  What makes a good anti-inflammatory drug target? , 2006, Drug discovery today.

[3]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[4]  A. Sands,et al.  Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.

[5]  Zhaowei Zhong,et al.  Quantitative analysis on the characteristics of targets with FDA approved drugs , 2007, International journal of biological sciences.

[6]  K. Foley,et al.  The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. , 2008, Experimental hematology.

[7]  X. Chen,et al.  TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..

[8]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[9]  Wei Wang,et al.  Learning the drug target‐likeness of a protein , 2007, Proteomics.

[10]  Yu Zong Chen,et al.  Support vector machines approach for predicting druggable proteins: recent progress in its exploration and investigation of its usefulness. , 2007, Drug discovery today.

[11]  Jürgen Drews,et al.  Strategic choices facing the pharmaceutical industry: A case for innovation , 1997 .

[12]  J. Harrington,et al.  High-throughput target discovery using cell-based genetics. , 2005, Drug discovery today.

[13]  X. Chen,et al.  SVM-Prot: web-based support vector machine software for functional classification of a protein from its primary sequence , 2003, Nucleic Acids Res..

[14]  A. Sands,et al.  In vivo drug target discovery: identifying the best targets from the genome. , 2001, Current opinion in biotechnology.

[15]  A G Murzin,et al.  SCOP: a structural classification of proteins database for the investigation of sequences and structures. , 1995, Journal of molecular biology.

[16]  C. Yap,et al.  Progress and problems in the exploration of therapeutic targets. , 2006, Drug discovery today.

[17]  S. Patterson,et al.  Proteomics: drug target discovery on an industrial scale. , 2002, Trends in biotechnology.

[18]  K. Mdluli,et al.  Novel targets for tuberculosis drug discovery. , 2006, Current opinion in pharmacology.

[19]  Juan Cui,et al.  Recent progresses in the application of machine learning approach for predicting protein functional class independent of sequence similarity , 2006, Proteomics.

[20]  Y. Z. Chen,et al.  Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics , 2006, Pharmacological Reviews.

[21]  J. Ng,et al.  Emerging high-throughput drug target validation technologies. , 2002, Drug discovery today.

[22]  M. Lindsay.  Finding new drug targets in the 21st century. , 2005, Drug discovery today.

[23]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[24]  Herbert Waldmann,et al.  Protein structure similarity clustering and natural product structure as guiding principles in drug discovery. , 2005, Drug discovery today.

[25]  R. Becker,et al.  Factor IXa inhibitors as novel anticoagulants. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[26]  J R Prous,et al.  Gateways to clinical trials. , 2005, Methods and findings in experimental and clinical pharmacology.

[27]  M Nakajima,et al.  [Matrix metalloproteinase inhibitors]. , 2000, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[28]  J. D. Elliott,et al.  Drug discovery in the next millennium. , 2000, Annual review of pharmacology and toxicology.

[29]  L. Rosenberg.  Physician-Scientists--Endangered and Essential , 1999, Science.

[30]  M. Austen,et al.  Phenotype-first screening for the identification of novel drug targets. , 2005, Drug discovery today.

[31]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[32]  C. Nicolette,et al.  The identification of clinically relevant markers and therapeutic targets. , 2003, Drug discovery today.

[33]  D. Wong,et al.  Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside , 2008, Clinical Cancer Research.

[34]  J. R.,et al.  Quantitative analysis , 1892, Nature.

[35]  A. Matter,et al.  Tumor angiogenesis as a therapeutic target. , 2001, Drug discovery today.

[36]  S. Knapp,et al.  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.

[37]  Andrey Rzhetsky,et al.  Quantitative systems-level determinants of human genes targeted by successful drugs. , 2008, Genome research.

[38]  M. Chiesi,et al.  Pharmacotherapy of obesity: targets and perspectives. , 2001, Trends in pharmacological sciences.

[39]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[40]  D. Ward,et al.  Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study , 2008, Journal of thrombosis and haemostasis : JTH.

[41]  Dalia Cohen,et al.  Functional genomics to new drug targets , 2004, Nature Reviews Drug Discovery.

[42]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[43]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[44]  J. Prous,et al.  Gateways to clinical trials. , 2006, Methods and findings in experimental and clinical pharmacology.

[45]  D. A. Quarles,et al.  Progress and problems , 1953, Electrical Engineering.

[46]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.